What caused GV.PA stock to rise intraday today?

The intraday rise to EUR 0.0018 was driven by unusually high volume of 38,489,238 shares. That level of activity often reflects short covering or retail momentum in microcaps, not confirmed company news.

How does Meyka AI rate GV.PA stock?

Meyka AI rates GV.PA with a score out of 100: 58.63 (Grade C+, Suggestion: HOLD). The grade blends sector comparison, financials, and forecast models and is informational only.

What is the 12‑month price forecast for GV.PA stock?

Meyka AI's forecast model projects a base case of EUR 0.0054 in 12 months, implying roughly 200.00% upside from EUR 0.0018. Forecasts are projections, not guarantees.

Is GV.PA a buy for long‑term investors?

GV.PA carries high risk: negative EPS, low market cap EUR 693,191, and low liquidity. For long‑term investors it is speculative and may require awaiting clear operational or funding improvements.

EU Stocks

GV.PA up 5.88% intraday on EURONEXT 29 Jan 2026: heavy volume signals trading interest

ByHuzaifa Zahoor January 29, 2026

GV.PA stock jumped 5.88% intraday on EURONEXT on 29 Jan 2026, trading at EUR 0.0018 as a heavy volume surge pushed shares to a day high of EUR 0.0020. Volume hit 38,489,238 shares, above the 50‑day average of 14,217,513, making Genomic Vision SA (GV.PA) one of Europe’s most active small‑caps today. This intraday move follows stretched 50‑ and 200‑day averages and continues a long downtrend from the €0.094 year high. We look at drivers, valuation, and what the volume means for short‑term traders and investors